^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Zonalta (Z-endoxifen hydrochloride)

    Company:
    Intas, Jina Pharma, National Cancer Institute
    Drug class:
    Estrogen receptor antagonist, Selective estrogen receptor modulator
    Related drugs:
    Apply
    Endoxifen in Adults With Hormone Receptor Positive Solid Tumors (NCT01273168)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    03/01/2011
    Primary completion :
    06/01/2020
    Completion :
    06/01/2026
    HER-2
    |
    tamoxifen • Zonalta (Z-endoxifen hydrochloride)
    Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery (NCT03317405)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    10/31/2018
    Primary completion :
    02/22/2021
    Completion :
    08/16/2025
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Zonalta (Z-endoxifen hydrochloride)
    Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (NCT02311933)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    05/28/2015
    Primary completion :
    11/06/2020
    Completion :
    02/04/2025
    ER • NCOA3
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)
    Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer (NCT01327781)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/26/2024
    Initiation :
    03/25/2011
    Primary completion :
    03/05/2017
    Completion :
    10/30/2024
    EGFR • HER-2 • ER • PGR • AKT1 • mTOR • IGF1R • NCOA3 • PI3K
    |
    ER positive • HER-2 expression • EGFR expression
    |
    Zonalta (Z-endoxifen hydrochloride)